TPB

In April 2026, TPB's stock declined by 15% due to broad investor risk-off selling, trade-policy uncertainty, a missed GAAP EPS consensus, soft Q1 2026 EBITDA guidance, and heavy strategic investments in the Modern Oral segment. In May 2026, the company reported Q1 2026 results with total net sales up 16.8% to $124.3 million and Modern Oral net sales up 133% to $52.0 million, subsequently raising its full-year 2026 Modern Oral guidance and introducing full-year Adjusted EBITDA guidance of $70–$90 million, also declaring a common stock dividend. Another common stock dividend was declared in July 2026. August 2026 saw Q2 2026 results with total consolidated net sales increasing by 22.6% to $142.9 million and Stoker's segment net sales rising by 54.5%, but the Zig-Zag segment net sales decreased by 24.8%, and profitability significantly contracted, with GAAP net income down 75.2% and Adjusted EBITDA falling by 50.0% due to Modern Oral investments and Zig-Zag softness. In September 2026, CEO Graham Purdy resigned, and Executive Chairman David E. Glazek was appointed as the new CEO; this news, combined with tightened full-year 2026 EBITDA guidance ($70–$80 million) due to higher freight costs and delayed onshoring benefits, led to a roughly 9% stock drop, though full-year Modern Oral sales guidance was reaffirmed. In October 2026, a regular quarterly dividend of $0.08 per common share was payable, with the stock price at $57.37 and a 52-week range of $54.69 to $146.90.